drugset / Trial / NCT01185288

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

NCT01185288

Phase 4 Completed 309 enrolled AbbVie
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will investigate the efficacy of both low and high doses of methotrexate (MTX) in combination with open-label adalimumab (ADA) in patients who have had an inadequate response to high dose of MTX. The study will also evaluate the pharmacokinetics and safety of the two regimens of MTX in combination with ADA in participants with rheumatoid arthritis (RA).

Timeline

Start
2010-09
Primary completion
2013-01
Completion
2013-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject Methotrexate Small molecule 7.5 mg Oral
Subject Methotrexate Small molecule 20 mg Oral

Indications